Trial Profile
Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Levomilnacipran (Primary) ; Duloxetine
- Indications Major depressive disorder; Stroke
- Focus Pharmacokinetics
- 05 Oct 2021 Planned End Date changed from 31 Jan 2020 to 1 May 2022.
- 05 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Dec 2019.